Stockscreener 앱 받기
2.24
2.61%
-0.06
시간 외 거래:
2.26
0.02
+0.89%
전일 마감가:
$2.30
열려 있는:
$2.31
하루 거래량:
44,652
Relative Volume:
0.31
시가총액:
$35.95M
수익:
$6.66M
순이익/손실:
$-25.52M
주가수익비율:
-1.8512
EPS:
-1.21
순현금흐름:
$-28.98M
1주 성능:
+0.00%
1개월 성능:
-1.32%
6개월 성능:
-29.34%
1년 성능:
-59.27%
1일 변동 폭
$2.22
$2.3827
1주일 범위
$2.21
$2.50
52주 변동 폭
$2.10
$7.40
Veru Inc Stock (VERU) Company Profile
명칭
Veru Inc
전화
(312) 595-9123
주소
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.24 | 36.92M | 6.66M | -25.52M | -28.98M | -1.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Canaccord Genuity | Buy |
| 2024-05-14 | 개시 | B. Riley Securities | Buy |
| 2024-03-28 | 개시 | Raymond James | Outperform |
| 2023-06-07 | 업그레이드 | Jefferies | Underperform → Hold |
| 2021-04-13 | 개시 | Jefferies | Buy |
| 2021-02-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-20 | 개시 | Oppenheimer | Outperform |
| 2018-07-03 | 개시 | Maxim Group | Buy |
모두보기
Veru Inc 주식(VERU)의 최신 뉴스
Veru Inc. (NASDAQ: VERU) Q1 2026 earnings call transcript - MSN
Veru Inc. (NASDAQ:VERU) Q1 2026 Earnings Call Transcript - Insider Monkey
Veru outlines new Phase IIb obesity trial and targets interim analysis in Q1 2027 while increasing cash reserves - MSN
Veru Q1 2026 Earnings Call Transcript - MarketBeat
Veru Inc. Charts Risky but Clearer Post-GLP-1 Path - TipRanks
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Veru Inc. (VERU) Advances Clinical Pipeline with Enobosarm and S - GuruFocus
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Adva - GuruFocus
VERU INC. SEC 10-Q Report - TradingView
VERU: No revenue, $5.3M net loss, $33M cash, strategic shift to drug development, going concern risk - TradingView
Veru (VERU) Q1 2026 Earnings Call Transcript - The Globe and Mail
VERU: Net loss narrowed, cash reserves rose, and enobosarm advances with FDA support for new trials - TradingView
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts - Investing.com
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts By Investing.com - Investing.com India
Veru reports Q1 EPS (26c) vs. (61c) last year - TipRanks
VERU INC (NASDAQ:VERU) Reports Narrower-Than-Expected Q1 Loss, Highlights Key Clinical Trial Timeline - ChartMill
Veru Inc. Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress - TradingView
VERU: Q1 net loss narrowed, cash rose, and new enobosarm/semaglutide trial to launch soon - TradingView
Veru (NASDAQ: VERU) narrows loss as enobosarm obesity program advances - Stock Titan
Veru Inc. Advances Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide for Weight Management in Older Adults with Obesity - Quiver Quantitative
Veru tests enobosarm to help older semaglutide users beat weight-loss plateau - Stock Titan
A Look at Veru's Upcoming Earnings Report - Benzinga
Veru Inc. (VERU.US) is scheduled to release its earnings report before the market opens on February 11. - 富途牛牛
Veru (VERU) Price Target Increased by 11.11% to 25.50 - Nasdaq
Veru Inc. to Host Conference Call for Fiscal 2026 First Quarter Financial Results and Business Update - Quiver Quantitative
Biopharma Veru sets Feb. 11 webcast on Q1 2026 results - Stock Titan
Published on: 2026-02-01 18:16:35 - baoquankhu1.vn
Wall Street Recap: Is Veru Inc a defensive stockJuly 2025 PostEarnings & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Block Trades: Will Veru Inc benefit from AI trends2025 Major Catalysts & Intraday High Probability Setup Alerts - baoquankhu1.vn
Analyzing Verano (OTCMKTS:VRNOF) & Veru (NASDAQ:VERU) - Defense World
Growth Report: Will Veru Inc benefit from AI trends2025 Buyback Activity & Fast Momentum Entry Tips - baoquankhu1.vn
Veru prices 1.4M shares at $3.00 in underwritten public offering - MSN
Targets Report: Will Veru Inc stock attract ESG investors2025 Market Sentiment & Real-Time Volume Analysis - Bộ Nội Vụ
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally - AOL.com
Is Veru Inc. stock a buy in volatile marketsJuly 2025 Final Week & Trade Opportunity Analysis - Улправда
Why Veru Inc. (FMW) stock trades below fair valueTrade Entry Report & Fast Entry High Yield Tips - ulpravda.ru
Is Veru Inc. stock attractive after correction2025 Macro Impact & Entry Point Confirmation Alerts - ulpravda.ru
ulpravda> 2026> How dovish Fed policy supports Veru Inc. (FMW) stockTake Profit & High Conviction Buy Zone Picks - ulpravda.ru
Why Veru Inc. (FMW) stock remains stableProfit Target & Low Risk High Reward Ideas - Улправда
Aug Drivers: Why Veru Inc. (FMW) stock remains stable2025 Stock Rankings & Risk Controlled Stock Alerts - ulpravda.ru
About UsGreat American Insurance GroupSpecialty Property & Casualty Insurance - FinancialContent
Veru Inc.Common Stock (NQ: VERU - FinancialContent
Why Vera Therapeutics Stock Zoomed Higher Today - AOL.com
Is Veru Inc. (FMW) stock prepared for digital transitionWeekly Market Report & Daily Entry Point Trade Alerts - ulpravda.ru
User | poteaudailynews.comVeru Inc.Common Stock (Nasdaq:VERU) Stock Quote - FinancialContent
What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now? - MSN
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Veru (NASDAQ:VERU) Share Price Crosses Below Two Hundred Day Moving Average – What’s Next? - Defense World
Veru outlines 72-week Phase IIb PLATEAU study targeting obesity plateau population following FDA guidance - MSN
Veru Inc | 4: Statement of changes in beneficial ownership of securities-Director Hyun Grace - 富途牛牛
Veru Inc. (NASDAQ:VERU) Q4 2025 Earnings Call Transcript - Insider Monkey
Veru Inc (VERU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):